首页 > 最新文献

Medical alphabet最新文献

英文 中文
Onset of Rheumatoid Arthritis with eye manifestations (clinical case report) 类风湿关节炎发病时伴有眼部表现(临床病例报告)
Pub Date : 2024-07-22 DOI: 10.33667/2078-5631-2024-10-53-56
A. I. Akulova, A. R. Avakian, G. R. Dolishniaia, N. M. Nikitina
Objective. Rheumatoid Arthritis may onset with ocular manifestations. The purpose of our work was presentation of clinical case of the onset of rheumatoid arthritis with an eye lesion.Materials and methods. A clinical case of rheumatoid arthritis with an atypical onset was analyzed. As well, a search and review of relevant literature was performed.Results. Patient with rheumatoid arthritis got bilateral ulcerous keratitis, refractory to conventional treatment and complicated by bilateral corneal perforation with iris prolapse. Due to the atypical clinical course of ophthalmic lesions being insusceptible of medical treatment, the patient was examined further. Laboratory immunological workup revealed positive rheumatoid factor, anti-CCP and anti-MCV antibodies. The typical symmetric presentation of arthritis developed 8 months after the onset of ophthalmic disorders. Baseline therapy of rheumatoid arthritis has demonstrated efficacy both in controlling the joint manifestations and preventing relapse of keratitis.Conclusion. The development of eye syndrome may precede articular manifestation of rheumatoid arthritis. While managing patients with recurrent bilateral keratitis, rheumatologic pathology should be suspected.
目的。类风湿性关节炎发病时可能伴有眼部表现。我们的研究旨在介绍一例类风湿性关节炎发病时伴有眼部病变的临床病例。我们对一例发病不典型的类风湿关节炎临床病例进行了分析。此外,还对相关文献进行了检索和回顾。类风湿性关节炎患者患有双侧溃疡性角膜炎,常规治疗无效,并发双侧角膜穿孔和虹膜脱垂。由于眼部病变的临床过程不典型,无法接受药物治疗,因此对患者进行了进一步检查。实验室免疫检查显示类风湿因子、抗CCP和抗MCV抗体阳性。典型的对称性关节炎是在眼部病变发生 8 个月后出现的。类风湿性关节炎的基线治疗在控制关节表现和预防角膜炎复发方面均有疗效。眼部综合征可能先于类风湿性关节炎的关节表现而出现。在治疗复发性双侧角膜炎患者时,应怀疑风湿病变。
{"title":"Onset of Rheumatoid Arthritis with eye manifestations (clinical case report)","authors":"A. I. Akulova, A. R. Avakian, G. R. Dolishniaia, N. M. Nikitina","doi":"10.33667/2078-5631-2024-10-53-56","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-53-56","url":null,"abstract":"Objective. Rheumatoid Arthritis may onset with ocular manifestations. The purpose of our work was presentation of clinical case of the onset of rheumatoid arthritis with an eye lesion.Materials and methods. A clinical case of rheumatoid arthritis with an atypical onset was analyzed. As well, a search and review of relevant literature was performed.Results. Patient with rheumatoid arthritis got bilateral ulcerous keratitis, refractory to conventional treatment and complicated by bilateral corneal perforation with iris prolapse. Due to the atypical clinical course of ophthalmic lesions being insusceptible of medical treatment, the patient was examined further. Laboratory immunological workup revealed positive rheumatoid factor, anti-CCP and anti-MCV antibodies. The typical symmetric presentation of arthritis developed 8 months after the onset of ophthalmic disorders. Baseline therapy of rheumatoid arthritis has demonstrated efficacy both in controlling the joint manifestations and preventing relapse of keratitis.Conclusion. The development of eye syndrome may precede articular manifestation of rheumatoid arthritis. While managing patients with recurrent bilateral keratitis, rheumatologic pathology should be suspected.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"25 22","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141815353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peculiarities of laboratory parameters dynamics during helicobacter pylori eradication in patients with rheumatoid arthritis 类风湿性关节炎患者根除幽门螺旋杆菌期间实验室指标动态的特殊性
Pub Date : 2024-07-22 DOI: 10.33667/2078-5631-2024-10-57-62
V. Aleksandrov, E. A. Zagorodneva, N. V. Aleksandrova, E. G. Cherkesova, L. N. Shilova, A. Aleksandrov
Helicobacter pylori (H. pylori) is able to participate in the pathogenesis of a number of autoimmune diseases, actively maintains chronic inflammation and stimulates the systemic immune response. The virulence factor of H. pylori is cytotoxin-associated gene A (CagA) is associated with more severe inflammatory reactions, increased risk of poor clinical outcomes and is able to influence the efficacy of infection eradication in patients with rheumatoid arthritis (RA).Purpose of the study. To evaluate laboratory parameters of H. pylori eradication efficacy in RA patients with chronic infection with the strain encoding cytotoxin-associated gene A.Materials and methods. Forty women with RA and confirmed chronic H. pylori infection were included in the study (mean age 55.5±8.7 years; mean disease duration 13.9±9.1 years; DAS-28–3.96±0.56). CagA-IgG associated H. pylori infection was diagnosed in 22 (group I, CagA+) and not diagnosed in 18 (group II, CagA-) patients. All RA patients underwent a course of H. pylori eradication therapy.Results. The process of H. pylori eradication had the most significant effect on laboratory parameters of CagA-negative RA patients (group II). In this group the levels of rheumatoid factor (p=0,028), C-reactive protein (CRP, p=0.001), interleukin-6 (IL-6, p=0.002), tumor necrosis factor alpha (p=0,023), angiopoietinlike protein type 3 (p=0.026) and antibodies to cyclic citrullinated peptide (ACCP, p=0,016) decreased significantly. In patients from group I (CagA+) most parameters remained practically unchanged (p>0.05), except for CRP (p=0.01) and IL-6 (p=0.011). In the short term, the success of eradication in CagA+ patients was significantly lower than in CagA- patients (p=0.033). Moreover, confirmation of successful eradication of H. pylori within the established period of time was extremely rare (p=0.009) in the combination of CagA+ and high titers of ACCP and antibodies to modified citrullinated vimentin.Conclusions. The effectiveness of H. pylori eradication in RA patients depends on the presence of chronic infection with the strain encoding the cytotoxin-associated gene A and the level of antibodies to citrullinated proteins, which should be taken into account when choosing the therapeutic effect on H. pylori in this group.
幽门螺杆菌(H. pylori)能够参与多种自身免疫性疾病的发病机制,积极维持慢性炎症并刺激全身免疫反应。幽门螺杆菌的毒力因子是细胞毒素相关基因 A(CagA),它与更严重的炎症反应、不良临床结果风险增加有关,并能影响类风湿性关节炎(RA)患者的感染根除效果。评估编码细胞毒素相关基因 A 菌株慢性感染的 RA 患者幽门螺杆菌根除效果的实验室参数。研究纳入了 40 名患有 RA 并确诊为慢性幽门螺杆菌感染的女性患者(平均年龄 55.5±8.7 岁;平均病程 13.9±9.1 年;DAS-28-3.96±0.56)。22例(I组,CagA+)患者确诊为CagA-IgG相关幽门螺杆菌感染,18例(II组,CagA-)患者未确诊。所有 RA 患者都接受了一个疗程的幽门螺杆菌根除治疗。结果显示,幽门螺杆菌根除疗法对 CagA 阴性 RA 患者(II 组)的实验室指标影响最大。在该组中,类风湿因子(p=0.028)、C反应蛋白(CRP,p=0.001)、白细胞介素-6(IL-6,p=0.002)、肿瘤坏死因子α(p=0.023)、血管生成素样蛋白3型(p=0.026)和环瓜氨酸肽抗体(ACCP,p=0.016)的水平显著下降。在第一组(CagA+)患者中,除 CRP(p=0.01)和 IL-6(p=0.011)外,大多数参数基本保持不变(p>0.05)。在短期内,CagA+ 患者的根除成功率明显低于 CagA- 患者(p=0.033)。此外,在 CagA+ 和高滴度 ACCP 及改良瓜氨酸波形蛋白抗体的组合中,在既定时间内成功根除幽门螺杆菌的确认极为罕见(p=0.009)。在RA患者中根除幽门螺杆菌的效果取决于编码细胞毒素相关基因A的菌株是否存在慢性感染以及瓜氨酸化蛋白抗体的水平,在选择对该群体幽门螺杆菌的治疗效果时应考虑到这一点。
{"title":"Peculiarities of laboratory parameters dynamics during helicobacter pylori eradication in patients with rheumatoid arthritis","authors":"V. Aleksandrov, E. A. Zagorodneva, N. V. Aleksandrova, E. G. Cherkesova, L. N. Shilova, A. Aleksandrov","doi":"10.33667/2078-5631-2024-10-57-62","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-57-62","url":null,"abstract":"Helicobacter pylori (H. pylori) is able to participate in the pathogenesis of a number of autoimmune diseases, actively maintains chronic inflammation and stimulates the systemic immune response. The virulence factor of H. pylori is cytotoxin-associated gene A (CagA) is associated with more severe inflammatory reactions, increased risk of poor clinical outcomes and is able to influence the efficacy of infection eradication in patients with rheumatoid arthritis (RA).Purpose of the study. To evaluate laboratory parameters of H. pylori eradication efficacy in RA patients with chronic infection with the strain encoding cytotoxin-associated gene A.Materials and methods. Forty women with RA and confirmed chronic H. pylori infection were included in the study (mean age 55.5±8.7 years; mean disease duration 13.9±9.1 years; DAS-28–3.96±0.56). CagA-IgG associated H. pylori infection was diagnosed in 22 (group I, CagA+) and not diagnosed in 18 (group II, CagA-) patients. All RA patients underwent a course of H. pylori eradication therapy.Results. The process of H. pylori eradication had the most significant effect on laboratory parameters of CagA-negative RA patients (group II). In this group the levels of rheumatoid factor (p=0,028), C-reactive protein (CRP, p=0.001), interleukin-6 (IL-6, p=0.002), tumor necrosis factor alpha (p=0,023), angiopoietinlike protein type 3 (p=0.026) and antibodies to cyclic citrullinated peptide (ACCP, p=0,016) decreased significantly. In patients from group I (CagA+) most parameters remained practically unchanged (p>0.05), except for CRP (p=0.01) and IL-6 (p=0.011). In the short term, the success of eradication in CagA+ patients was significantly lower than in CagA- patients (p=0.033). Moreover, confirmation of successful eradication of H. pylori within the established period of time was extremely rare (p=0.009) in the combination of CagA+ and high titers of ACCP and antibodies to modified citrullinated vimentin.Conclusions. The effectiveness of H. pylori eradication in RA patients depends on the presence of chronic infection with the strain encoding the cytotoxin-associated gene A and the level of antibodies to citrullinated proteins, which should be taken into account when choosing the therapeutic effect on H. pylori in this group.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"26 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141815476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteopoikilia in the practice of a rheumatologist 风湿病医生诊疗中的骨质疏松症
Pub Date : 2024-07-22 DOI: 10.33667/2078-5631-2024-10-51-53
N. Y. Tikhomirova, L. N. Eliseeva, N. Belozerova, E. S. Kameneva, V. A. Shkokov, T. I. Frolova
Osteopoikilia (OPC) is a rare, benign autosomal dominant disease characterized by sclerotic bone lesions, which usually proceeds asymptomatically. It is usually diagnosed by accident with conventional radiography. In most patients, the disease is asymptomatic, but some may complain of mild joint pain and swelling. Differential diagnoses of the disease include osteoblastic metastases, primary bone tumor, mastocytosis, tuberous sclerosis, synovial chondromatosis and melanostasis. In the literature, we have found reports of the coexistence of OPC with rheumatological diseases such as fibromyalgia, reactive arthritis, familial Mediterranean fever, psoriatic arthritis, rheumatoid arthritis, seronegative spondyloarthritis. Thus, the clinical case we observed is interesting not only from the standpoint of the importance of establishing a clinical diagnosis, but also the timeliness of starting treatment, which affects the prognosis of the disease.
骨质疏松症(OPC)是一种罕见的良性常染色体显性遗传病,以骨质硬化性病变为特征,通常无症状。该病通常是通过常规放射线检查意外确诊的。大多数患者没有症状,但有些患者可能会抱怨关节轻微疼痛和肿胀。该病的鉴别诊断包括成骨细胞转移、原发性骨肿瘤、肥大细胞增多症、结节性硬化症、滑膜软骨瘤病和黑变病。在文献中,我们发现有 OPC 与纤维肌痛、反应性关节炎、家族性地中海热、银屑病关节炎、类风湿性关节炎、血清阴性脊柱关节炎等风湿性疾病并存的报道。因此,我们所观察到的临床病例不仅从临床诊断的重要性角度来看很有意义,而且从开始治疗的及时性角度来看也很有意义,因为这影响到疾病的预后。
{"title":"Osteopoikilia in the practice of a rheumatologist","authors":"N. Y. Tikhomirova, L. N. Eliseeva, N. Belozerova, E. S. Kameneva, V. A. Shkokov, T. I. Frolova","doi":"10.33667/2078-5631-2024-10-51-53","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-51-53","url":null,"abstract":"Osteopoikilia (OPC) is a rare, benign autosomal dominant disease characterized by sclerotic bone lesions, which usually proceeds asymptomatically. It is usually diagnosed by accident with conventional radiography. In most patients, the disease is asymptomatic, but some may complain of mild joint pain and swelling. Differential diagnoses of the disease include osteoblastic metastases, primary bone tumor, mastocytosis, tuberous sclerosis, synovial chondromatosis and melanostasis. In the literature, we have found reports of the coexistence of OPC with rheumatological diseases such as fibromyalgia, reactive arthritis, familial Mediterranean fever, psoriatic arthritis, rheumatoid arthritis, seronegative spondyloarthritis. Thus, the clinical case we observed is interesting not only from the standpoint of the importance of establishing a clinical diagnosis, but also the timeliness of starting treatment, which affects the prognosis of the disease.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"25 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141814523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal nature of pain syndrome in patients with rheumatoid arthritis in relation to the course of the disease and clinical characteristics 类风湿关节炎患者疼痛综合征的多模式性质与病程和临床特征的关系
Pub Date : 2024-07-22 DOI: 10.33667/2078-5631-2024-10-37-42
K. R. Zagretdinova, Z. Gabdullina, E. Sukhorukova, E. S. Zamanova, R. Z. Abdrakipov, S. A. Lapshina
Purpose of the study. To evaluate the character of pain syndrome in patients with rheumatoid arthritis in correlation with the course of the disease and comorbid pathology.Material and methods. Sixty-six patients with a verified diagnosis of RA were examined. Of them 84.9% were women (n=56) and 15.1% men (n=10). The median age was 59 [52; 63] years. Disease activity was assessed by DAS28-CRP, with a median of 5.2 [4.54; 6.0]. Patients with moderate (31.8%) and high activity (57.5%) predominated. Disease duration averaged Me 156 [93; 246] months. Seropositive RA was suffered by 89.3% of patients. The distribution by radiological stage was as follows: 2 radiological stage – 36.3% (n=24), 3 radiological stage – 30.3% (n=20), 4 radiological stage – 33.4% (n=22). Baseline anti-inflammatory therapy was taken by 84.8% of patients (n=56), genetically engineered biological drugs were received by 28.7% (n=16). To assess the multicomponent nature of pain syndrome, the following were used: Pain Detect questionnaire — to verify neuropathic pain (NP), CSI questionnaire — to verify central sensitisation (CS). The EQ-5D-3L questionnaire was used to assess quality of life, and the Charlson index was used to assess comorbid pathology. Structural changes were assessed by modified Sharpe method on hand and foot radiographs, synovium vascularisation was assessed by joint ultrasound.Results. 84.8% of patients had pain syndrome of mixed nature. NP correlated with pain intensity by VAS (rSp=0.458, p<0.001), DAS28-CRP (rSp=0.509, p<0.001), number of peripheral arthritis (rSp=0, 414, p<0.001), number of comorbidities (rSp=0.337, p=0.006), Charlson index (rSp=0.323, p=0.009), EQ-5D-3L (rSp= –0.268, p=0.031). CS–with VAS pain intensity (rSp=0.250, p=0.045), DAS28-CRP (rSp=0.251, p=0.044), number of painful joints (rSp=0.353, p=0.004), number of comorbidities (rSp=0.368, p=0.003), BMI (rSp=0.266, p=0.032), systolic blood pressure level (rSp=0.403, p<0.001), number of erosions on hand and foot radiographs (rSp= –0.299, p=0.016), EQ-5D-3L (rCp= –0.408, p<0.001). Patients with the presence of synovial vascularization by ultrasound had three-component pain in more than half of cases, and the combination of inflammatory pain and CS did not occur in them.Conclusions. 84.8% of patients had multicomponent pain, with pain associated only with clinical parameters of disease activity. Associated pathology and local chronic inflammation in the joint potentiate the development of other types of pain and have a mutual negative influence.
研究目的评估类风湿关节炎患者疼痛综合征的特征与病程和合并病理的相关性。对 66 名确诊为类风湿关节炎的患者进行了检查。其中 84.9% 为女性(56 人),15.1% 为男性(10 人)。年龄中位数为59 [52; 63]岁。疾病活动性由 DAS28-CRP 评估,中位数为 5.2 [4.54; 6.0]。患者以中度(31.8%)和高度(57.5%)活动性为主。病程平均为 156 [93; 246] 个月。89.3%的患者血清反应呈阳性。放射学分期分布如下放射学 2 期--36.3%(24 人),放射学 3 期--30.3%(20 人),放射学 4 期--33.4%(22 人)。84.8%的患者(人数=56)接受了基线抗炎治疗,28.7%的患者(人数=16)接受了基因工程生物药物治疗。为评估疼痛综合征的多成分性质,采用了以下方法:疼痛检测问卷--核实神经病理性疼痛(NP),CSI问卷--核实中枢敏化(CS)。EQ-5D-3L 问卷用于评估生活质量,Charlson 指数用于评估合并病症。用改良夏普法评估手部和足部X光片的结构变化,用关节超声波评估滑膜血管情况。84.8%的患者患有混合性疼痛综合征。NP与VAS疼痛强度(rSp=0.458,p<0.001)、DAS28-CRP(rSp=0.509,p<0.001)、外周关节炎数量(rSp=0,414,p<0.001)、合并症数量(rSp=0.337,p=0.006)、Charlson指数(rSp=0.323,p=0.009)、EQ-5D-3L(rSp= -0.268,p=0.031)相关。CS-与 VAS 疼痛强度(rSp=0.250,p=0.045)、DAS28-CRP(rSp=0.251,p=0.044)、疼痛关节数量(rSp=0.353,p=0.004)、合并症数量(rSp=0.368,p=0.003)、体重指数(rSp=0.266,p=0.032)、收缩压水平(rSp=0.403,p<0.001)、手足X光片糜烂数量(rSp= -0.299,p=0.016)、EQ-5D-3L(rCp= -0.408,p<0.001)。超声检查发现滑膜血管化的患者中,半数以上有三组份疼痛,炎症性疼痛和 CS 的组合在他们身上没有出现。84.8%的患者有多组分疼痛,疼痛仅与疾病活动的临床参数相关。相关病理和关节局部慢性炎症会诱发其他类型的疼痛,并相互产生负面影响。
{"title":"Multimodal nature of pain syndrome in patients with rheumatoid arthritis in relation to the course of the disease and clinical characteristics","authors":"K. R. Zagretdinova, Z. Gabdullina, E. Sukhorukova, E. S. Zamanova, R. Z. Abdrakipov, S. A. Lapshina","doi":"10.33667/2078-5631-2024-10-37-42","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-37-42","url":null,"abstract":"Purpose of the study. To evaluate the character of pain syndrome in patients with rheumatoid arthritis in correlation with the course of the disease and comorbid pathology.Material and methods. Sixty-six patients with a verified diagnosis of RA were examined. Of them 84.9% were women (n=56) and 15.1% men (n=10). The median age was 59 [52; 63] years. Disease activity was assessed by DAS28-CRP, with a median of 5.2 [4.54; 6.0]. Patients with moderate (31.8%) and high activity (57.5%) predominated. Disease duration averaged Me 156 [93; 246] months. Seropositive RA was suffered by 89.3% of patients. The distribution by radiological stage was as follows: 2 radiological stage – 36.3% (n=24), 3 radiological stage – 30.3% (n=20), 4 radiological stage – 33.4% (n=22). Baseline anti-inflammatory therapy was taken by 84.8% of patients (n=56), genetically engineered biological drugs were received by 28.7% (n=16). To assess the multicomponent nature of pain syndrome, the following were used: Pain Detect questionnaire — to verify neuropathic pain (NP), CSI questionnaire — to verify central sensitisation (CS). The EQ-5D-3L questionnaire was used to assess quality of life, and the Charlson index was used to assess comorbid pathology. Structural changes were assessed by modified Sharpe method on hand and foot radiographs, synovium vascularisation was assessed by joint ultrasound.Results. 84.8% of patients had pain syndrome of mixed nature. NP correlated with pain intensity by VAS (rSp=0.458, p<0.001), DAS28-CRP (rSp=0.509, p<0.001), number of peripheral arthritis (rSp=0, 414, p<0.001), number of comorbidities (rSp=0.337, p=0.006), Charlson index (rSp=0.323, p=0.009), EQ-5D-3L (rSp= –0.268, p=0.031). CS–with VAS pain intensity (rSp=0.250, p=0.045), DAS28-CRP (rSp=0.251, p=0.044), number of painful joints (rSp=0.353, p=0.004), number of comorbidities (rSp=0.368, p=0.003), BMI (rSp=0.266, p=0.032), systolic blood pressure level (rSp=0.403, p<0.001), number of erosions on hand and foot radiographs (rSp= –0.299, p=0.016), EQ-5D-3L (rCp= –0.408, p<0.001). Patients with the presence of synovial vascularization by ultrasound had three-component pain in more than half of cases, and the combination of inflammatory pain and CS did not occur in them.Conclusions. 84.8% of patients had multicomponent pain, with pain associated only with clinical parameters of disease activity. Associated pathology and local chronic inflammation in the joint potentiate the development of other types of pain and have a mutual negative influence.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"25 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141816977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney autotransplantation with renal arteries injury in a patient with Takayasu arteritis 一名高安动脉炎患者的肾脏自体移植与肾动脉损伤
Pub Date : 2024-07-22 DOI: 10.33667/2078-5631-2024-10-43-47
I. Borodina, A. A. Popov, B. Fadin, V. V. Rzhannikov, A. N. Ageev, L. Shardina
Takayasu arteritis (AT) is a systemic vasculitis of large vessels. As a rule, AT develops in patients under 50 years of age and is characterized by vasculitis, often granulomatous, with a predominant lesion of the aorta and/or its main branches. The article describes a clinical case of a patient with bilateral lesions of the renal arteries caused by AT, who underwent kidney autotransplantation. The first manifestations of psoriasis in the patient occurred after psychological stress 15 years after surgery. The described clinical observation of multi-stage surgical treatment of Takayasu arteritis, which ended favorably, is presented by us in order to demonstrate the capabilities of modern medical technologies in both diagnosis and surgical treatment of multi-vessel lesions in Takayasu arteritis. The combination of AT and psoriasis is a rare pathology, the problems of diagnosis and treatment of which require further study.
高安动脉炎(AT)是一种全身性大血管炎。通常,高安动脉炎多发于 50 岁以下的患者,其特点是血管炎,常为肉芽肿性,主要病变为主动脉和/或其主要分支。文章描述了一个由 AT 引起双侧肾动脉病变的临床病例,该患者接受了肾脏自体移植手术。术后 15 年,患者在心理压力下首次出现银屑病症状。我们介绍了多阶段手术治疗高安动脉炎的临床观察结果,结果良好,旨在展示现代医疗技术在诊断和手术治疗高安动脉炎多血管病变方面的能力。高安动脉炎和银屑病的结合是一种罕见的病理现象,其诊断和治疗问题需要进一步研究。
{"title":"Kidney autotransplantation with renal arteries injury in a patient with Takayasu arteritis","authors":"I. Borodina, A. A. Popov, B. Fadin, V. V. Rzhannikov, A. N. Ageev, L. Shardina","doi":"10.33667/2078-5631-2024-10-43-47","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-43-47","url":null,"abstract":"Takayasu arteritis (AT) is a systemic vasculitis of large vessels. As a rule, AT develops in patients under 50 years of age and is characterized by vasculitis, often granulomatous, with a predominant lesion of the aorta and/or its main branches. The article describes a clinical case of a patient with bilateral lesions of the renal arteries caused by AT, who underwent kidney autotransplantation. The first manifestations of psoriasis in the patient occurred after psychological stress 15 years after surgery. The described clinical observation of multi-stage surgical treatment of Takayasu arteritis, which ended favorably, is presented by us in order to demonstrate the capabilities of modern medical technologies in both diagnosis and surgical treatment of multi-vessel lesions in Takayasu arteritis. The combination of AT and psoriasis is a rare pathology, the problems of diagnosis and treatment of which require further study.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"28 28","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141814501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Современные маркеры диагностики сочетания анкилозирующего спондилита и воспалительных заболеваний кишечника 强直性脊柱炎和炎症性肠病合并症的现有诊断指标
Pub Date : 2024-07-22 DOI: 10.33667/2078-5631-2024-10-47-50
D. Tarasova, L. N. Shilova
The problem of the combination of ankylosing spondylitis (AS) and inflammatory bowel diseases (IBD) is interdisciplinary. Modern approaches to studying this issue among rheumatologists and gastroenterologists are somewhat different. The combination of these two pathologies is a potential factor for a more severe course of these diseases. The article provides an overview of some markers that have shown high specificity in the diagnosis of AS and IBD
强直性脊柱炎(AS)与炎症性肠病(IBD)的结合问题是一个跨学科的问题。风湿病学家和肠胃病学家研究这一问题的现代方法有些不同。这两种病症的结合是导致这些疾病病程更加严重的潜在因素。文章概述了在诊断强直性脊柱炎和 IBD 时显示出高度特异性的一些标记物
{"title":"Современные маркеры диагностики сочетания анкилозирующего спондилита и воспалительных заболеваний кишечника","authors":"D. Tarasova, L. N. Shilova","doi":"10.33667/2078-5631-2024-10-47-50","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-47-50","url":null,"abstract":"The problem of the combination of ankylosing spondylitis (AS) and inflammatory bowel diseases (IBD) is interdisciplinary. Modern approaches to studying this issue among rheumatologists and gastroenterologists are somewhat different. The combination of these two pathologies is a potential factor for a more severe course of these diseases. The article provides an overview of some markers that have shown high specificity in the diagnosis of AS and IBD","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"48 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141815055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative characteristics of the effectiveness of drugs for the treatment of alopecia areata in childhood 治疗儿童斑秃药物疗效的比较特点
Pub Date : 2024-07-21 DOI: 10.33667/2078-5631-2024-9-66-69
N. Murashkin, A. M. Dogov
Alopecia areata (АА) is an autoimmune inflammatory disease with an established genetic predisposition, which is based on the lesion of hair follicles, leading to persistent or temporary hair loss. To date, treatment of АA in children, is limited to the use in most cases of external hormonal therapy in the form сream or the prescription of intradermal injections of GCS in outpatient conditions. However, data on the effectiveness of this group of drugs in severe forms of AA flow are not fully studied. There is an open question of the choice of the most preferred drug in patients simultaneously with a severe flow of AA and a severe form of atopic dermatitis. Another interesting variant of treatment of AA is the drug Dupilumab. (blocker IL-4 and IL-13). The mechanism of action of dupilumab at АA remains unknown, and its effect on TH-type 2 is assumed.Purpose of the study. To conduct a comparative performance characterization of: external GCS (Clobetazole) and injectable GCS (Betamethazone) for treatment of AA in children; Tofacitinib treatment for children with alopecia and the presence or absence of atopic dermatitis in the form of a concomitant disease; use of Dupilumaba to treat children with AA.Materials and methods. The research sample includes 420 patients. By the nature of the lesion, we considered three types of alopecia: spotted, total and universal. Patient data is taken from the register of AA patients in children. [13]. The effectiveness of the treatment was assessed on the scale SALT [14]. Patients were monitored for six months.Results. Use of intradermal injections GKS (Betamethazone), more effective than outdoor GKS (Clobetazole). In patients with atopic dermatitis, the efficacy of Tofacitinib for AA treatment is reliably higher than in patients without atopic dermatitis. Dupilumab may be a drug of choice for treating patients with a total and universal form of AA.Conclusion. Additional randomized controlled trials are needed to assess the long-term efficacy of drugs such as Tofacitinib and Dupilumab.
斑秃(АА)是一种具有遗传倾向的自身免疫性炎症疾病,它以毛囊病变为基础,导致持续性或暂时性脱发。迄今为止,对儿童АA 的治疗仅限于在大多数情况下使用外用激素疗法,即使用сream 或在门诊处方皮内注射 GCS。然而,关于这类药物对严重 AA 流的有效性的数据尚未得到充分研究。对于同时患有严重 AA 流和严重特应性皮炎的患者,如何选择最合适的药物是一个悬而未决的问题。另一种治疗 AA 的有趣变体是药物 Dupilumab。(IL-4和IL-13阻断剂)。Dupilumab在АA的作用机制尚不清楚,其对TH-2型的影响是假定的。对以下几种药物的性能特点进行比较:外用GCS(氯贝他唑)和注射用GCS(倍他米松)治疗儿童AA;托法替尼治疗脱发儿童,以及是否存在特应性皮炎形式的伴随疾病;使用杜匹卢单抗治疗儿童AA。研究样本包括 420 名患者。根据病变的性质,我们将脱发分为三种类型:斑秃、全秃和普秃。患者数据来自儿童 AA 患者登记册。[13].治疗效果根据 SALT量表进行评估[14]。对患者进行了为期 6 个月的监测。皮内注射 GKS(倍他米松)比室外注射 GKS(氯贝他唑)更有效。在特应性皮炎患者中,托法替尼治疗 AA 的疗效明显高于无特应性皮炎的患者。结论:杜匹单抗可能是治疗全身性 AA 患者的首选药物。需要进行更多的随机对照试验,以评估托法替尼和度普卢单抗等药物的长期疗效。
{"title":"Comparative characteristics of the effectiveness of drugs for the treatment of alopecia areata in childhood","authors":"N. Murashkin, A. M. Dogov","doi":"10.33667/2078-5631-2024-9-66-69","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-9-66-69","url":null,"abstract":"Alopecia areata (АА) is an autoimmune inflammatory disease with an established genetic predisposition, which is based on the lesion of hair follicles, leading to persistent or temporary hair loss. To date, treatment of АA in children, is limited to the use in most cases of external hormonal therapy in the form сream or the prescription of intradermal injections of GCS in outpatient conditions. However, data on the effectiveness of this group of drugs in severe forms of AA flow are not fully studied. There is an open question of the choice of the most preferred drug in patients simultaneously with a severe flow of AA and a severe form of atopic dermatitis. Another interesting variant of treatment of AA is the drug Dupilumab. (blocker IL-4 and IL-13). The mechanism of action of dupilumab at АA remains unknown, and its effect on TH-type 2 is assumed.Purpose of the study. To conduct a comparative performance characterization of: external GCS (Clobetazole) and injectable GCS (Betamethazone) for treatment of AA in children; Tofacitinib treatment for children with alopecia and the presence or absence of atopic dermatitis in the form of a concomitant disease; use of Dupilumaba to treat children with AA.Materials and methods. The research sample includes 420 patients. By the nature of the lesion, we considered three types of alopecia: spotted, total and universal. Patient data is taken from the register of AA patients in children. [13]. The effectiveness of the treatment was assessed on the scale SALT [14]. Patients were monitored for six months.Results. Use of intradermal injections GKS (Betamethazone), more effective than outdoor GKS (Clobetazole). In patients with atopic dermatitis, the efficacy of Tofacitinib for AA treatment is reliably higher than in patients without atopic dermatitis. Dupilumab may be a drug of choice for treating patients with a total and universal form of AA.Conclusion. Additional randomized controlled trials are needed to assess the long-term efficacy of drugs such as Tofacitinib and Dupilumab.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"36 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience in using laser to correct periorbital and temporal veins 使用激光矫正眶周和颞部静脉的经验
Pub Date : 2024-07-21 DOI: 10.33667/2078-5631-2024-9-95-96
A. S. Popova, N. Gryazeva, A. G. Stenko
This article presents the experience of using laser for the correction of periorbital and temporal veins. Clinical cases are presented indicating the treatment parameters used. Mono mode and multiplex modes were used.
本文介绍了使用激光矫正眶周和颞部静脉的经验。文中介绍的临床病例说明了所使用的治疗参数。使用了单模式和多模式。
{"title":"Experience in using laser to correct periorbital and temporal veins","authors":"A. S. Popova, N. Gryazeva, A. G. Stenko","doi":"10.33667/2078-5631-2024-9-95-96","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-9-95-96","url":null,"abstract":"This article presents the experience of using laser for the correction of periorbital and temporal veins. Clinical cases are presented indicating the treatment parameters used. Mono mode and multiplex modes were used.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"88 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors 类风湿性关节炎中的促炎细胞因子:与 Janus 激酶和白细胞介素 6 抑制剂疗法相抗衡的动态变化
Pub Date : 2024-07-21 DOI: 10.33667/2078-5631-2024-10-31-36
A. A. Baranov, N. Lapkina, E. A. Leontyeva, A. Karateev, A. A. Kolinyko, A. P. Pavluchkov, A. Artyuhov, I. A. Gorohov
Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role in the pathogenesis of RA. JAK inhibitors and bDMARD are aimed at suppressing various pathological reactions caused by them.The aim of the study. To determine the effect of therapy with JAK and IL-6 inhibitors on the concentration of proinflammatory cytokines in RA patients in real clinical practice.Materials and methods. The study included 30 patients with a reliable diagnosis of RA, advanced stage of disease, with moderate or high RA activity and ineffectiveness of previous therapy with csDMARD or bDMARD for at least 6 months. 10 patients received TOFA at a dose of 5 mg twice daily 10 received UPA at a dose of 15 mg once daily and 10 were on OKZ therapy at a dose of 64 mg subcutaneously every 4 weeks. Studies were performed before treatment, after 3 and 6 months of therapy. The levels of IL-1β, IL-6, IL-17A, IL-17F, IL-23, IL-31, IL-33, INF-γ, TNF-α in serum were investigated using multiplex xMAR technology on Bio-PlexTM 200 System analyser (BIO-RAD, USA).Results. In all groups of patients after 3 and 6 months from the start of therapy, there was a significant decrease in the RA activity index compared to baseline values. The concentration of IL-1β, IL-17A, IL-17F and IL-23 did not change significantly during treatment with any of the drugs. IL-6 values on TOFA background significantly decreased after 3 and 6 months of follow-up compared to the baseline level. UPA therapy had no effect on IL-6 level during the whole observation period, and against the background of OKZ application its values significantly increased after 3 months, and after 6 months – decreased, remaining higher than the initial values. The concentration of IL-31 after 3 months of TOFA treatment significantly decreased (respectively: 6.95 (3.85; 17.72) pg/ml and 3.00 (1.50; 3.85) pg/ml, p<0.05), and after 6 months – increased, but remained lower than baseline (5.09 (3.85; 6.33) pg/ml, p<0.05). IL-33 level on the background of UPA decreased and after 6 months was significantly lower than baseline (1.11 (0.86; 3.95) pg/ ml; 1.05 (0.37; 3.95) and 0.37 (0.12; 1.23) pg/ml, p<0.05). The concentration of INF-γ after 3 and 6 months of TOFA administration decreased significantly compared to the start of therapy (2.05 (1.48; 3.19) pg/ml; 0.99 (0.49; 2.05) pg/ml and 0.99 (0.49; 2.62) pg/ml, p<0.05). Treatment with OKZ resulted in increased TNF-α levels after 6 months compared to baseline values of 0.79 (0.41; 0.98) pg/ml and 1.23 (0.67; 2.06) pg/ml, p<0.05.Conclusions. The use of TOFA, UPA and OKZ in RA patients has a positive effect on disease activity, but has different effects on the level of proinflammatory cytokines in serum.
血清和滑膜液中促炎细胞因子的分泌增加在RA的发病机制中起着重要作用。JAK 抑制剂和 bDMARD 旨在抑制由其引起的各种病理反应。在实际临床实践中确定 JAK 和 IL-6 抑制剂治疗对 RA 患者促炎细胞因子浓度的影响。研究纳入了 30 名确诊为 RA、疾病晚期、具有中度或高度 RA 活动性、既往使用 csDMARD 或 bDMARD 治疗至少 6 个月无效的患者。其中 10 名患者接受 TOFA 治疗,剂量为 5 毫克,每天两次;10 名患者接受 UPA 治疗,剂量为 15 毫克,每天一次;10 名患者接受 OKZ 治疗,剂量为 64 毫克,每 4 周皮下注射一次。研究分别在治疗前、治疗 3 个月和 6 个月后进行。在 Bio-PlexTM 200 系统分析仪(美国 BIO-RAD)上使用多重 xMAR 技术检测了血清中 IL-1β、IL-6、IL-17A、IL-17F、IL-23、IL-31、IL-33、INF-γ、TNF-α 的水平。自治疗开始 3 个月和 6 个月后,各组患者的 RA 活动指数与基线值相比均显著下降。在使用任何一种药物治疗期间,IL-1β、IL-17A、IL-17F 和 IL-23 的浓度均无明显变化。与基线水平相比,TOFA背景下的IL-6值在随访3个月和6个月后明显下降。在整个观察期间,UPA疗法对IL-6水平没有影响,而在应用OKZ的背景下,IL-6的数值在3个月后明显升高,6个月后有所下降,但仍高于初始值。经过 3 个月的 TOFA 治疗后,IL-31 的浓度明显下降(分别为 6.95(3.85;6.85;6.95;6.85;6.85):6.95 (3.85; 17.72) pg/ml 和 3.00 (1.50; 3.85) pg/ml,p<0.05),6 个月后有所上升,但仍低于基线值(5.09 (3.85; 6.33) pg/ml,p<0.05)。在 UPA 的背景下,IL-33 水平下降,6 个月后明显低于基线(1.11 (0.86; 3.95) pg/ml; 1.05 (0.37; 3.95) and 0.37 (0.12; 1.23) pg/ml,p<0.05)。与开始治疗时相比,服用 TOFA 3 个月和 6 个月后 INF-γ 的浓度明显下降(2.05 (1.48; 3.19) pg/ml; 0.99 (0.49; 2.05) pg/ml 和 0.99 (0.49; 2.62) pg/ml,p<0.05)。与基线值相比,OKZ治疗6个月后TNF-α水平升高,分别为0.79 (0.41; 0.98) pg/ml和1.23 (0.67; 2.06) pg/ml,p<0.05。对RA患者使用TOFA、UPA和OKZ对疾病活动有积极影响,但对血清中的促炎细胞因子水平有不同影响。
{"title":"Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors","authors":"A. A. Baranov, N. Lapkina, E. A. Leontyeva, A. Karateev, A. A. Kolinyko, A. P. Pavluchkov, A. Artyuhov, I. A. Gorohov","doi":"10.33667/2078-5631-2024-10-31-36","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-10-31-36","url":null,"abstract":"Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role in the pathogenesis of RA. JAK inhibitors and bDMARD are aimed at suppressing various pathological reactions caused by them.The aim of the study. To determine the effect of therapy with JAK and IL-6 inhibitors on the concentration of proinflammatory cytokines in RA patients in real clinical practice.Materials and methods. The study included 30 patients with a reliable diagnosis of RA, advanced stage of disease, with moderate or high RA activity and ineffectiveness of previous therapy with csDMARD or bDMARD for at least 6 months. 10 patients received TOFA at a dose of 5 mg twice daily 10 received UPA at a dose of 15 mg once daily and 10 were on OKZ therapy at a dose of 64 mg subcutaneously every 4 weeks. Studies were performed before treatment, after 3 and 6 months of therapy. The levels of IL-1β, IL-6, IL-17A, IL-17F, IL-23, IL-31, IL-33, INF-γ, TNF-α in serum were investigated using multiplex xMAR technology on Bio-PlexTM 200 System analyser (BIO-RAD, USA).Results. In all groups of patients after 3 and 6 months from the start of therapy, there was a significant decrease in the RA activity index compared to baseline values. The concentration of IL-1β, IL-17A, IL-17F and IL-23 did not change significantly during treatment with any of the drugs. IL-6 values on TOFA background significantly decreased after 3 and 6 months of follow-up compared to the baseline level. UPA therapy had no effect on IL-6 level during the whole observation period, and against the background of OKZ application its values significantly increased after 3 months, and after 6 months – decreased, remaining higher than the initial values. The concentration of IL-31 after 3 months of TOFA treatment significantly decreased (respectively: 6.95 (3.85; 17.72) pg/ml and 3.00 (1.50; 3.85) pg/ml, p<0.05), and after 6 months – increased, but remained lower than baseline (5.09 (3.85; 6.33) pg/ml, p<0.05). IL-33 level on the background of UPA decreased and after 6 months was significantly lower than baseline (1.11 (0.86; 3.95) pg/ ml; 1.05 (0.37; 3.95) and 0.37 (0.12; 1.23) pg/ml, p<0.05). The concentration of INF-γ after 3 and 6 months of TOFA administration decreased significantly compared to the start of therapy (2.05 (1.48; 3.19) pg/ml; 0.99 (0.49; 2.05) pg/ml and 0.99 (0.49; 2.62) pg/ml, p<0.05). Treatment with OKZ resulted in increased TNF-α levels after 6 months compared to baseline values of 0.79 (0.41; 0.98) pg/ml and 1.23 (0.67; 2.06) pg/ml, p<0.05.Conclusions. The use of TOFA, UPA and OKZ in RA patients has a positive effect on disease activity, but has different effects on the level of proinflammatory cytokines in serum.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"17 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modern approaches to acne therapy: review of clinical recommendations and analysis of clinical cases 痤疮治疗的现代方法:临床建议回顾与临床病例分析
Pub Date : 2024-07-21 DOI: 10.33667/2078-5631-2024-9-61-65
L. S. Kruglova, N. Gryazeva
This article provides an overview of modern guidelines for acne treatment. The issues of prescribing both topical and systemic acne therapy are discussed. Particular attention is paid to systemic isotretinoin therapy. Clinical examples of the use of the drug Erase for acne of moderate and severe severity are discussed.
本文概述了现代痤疮治疗指南。文章讨论了痤疮局部治疗和全身治疗的处方问题。其中特别关注系统性异维A酸治疗。文章还讨论了使用 Erase 药物治疗中度和重度痤疮的临床案例。
{"title":"Modern approaches to acne therapy: review of clinical recommendations and analysis of clinical cases","authors":"L. S. Kruglova, N. Gryazeva","doi":"10.33667/2078-5631-2024-9-61-65","DOIUrl":"https://doi.org/10.33667/2078-5631-2024-9-61-65","url":null,"abstract":"This article provides an overview of modern guidelines for acne treatment. The issues of prescribing both topical and systemic acne therapy are discussed. Particular attention is paid to systemic isotretinoin therapy. Clinical examples of the use of the drug Erase for acne of moderate and severe severity are discussed.","PeriodicalId":18337,"journal":{"name":"Medical alphabet","volume":"64 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141817720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical alphabet
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1